Loading
JT
Jounce Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by TANG KEVIN C, was filed 14 Mar 2023.
Jounce Therapeutics, Inc.: what insiders have been doing
Jounce Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Cambridge, United States, founded in 2013. Its insiders report their share dealings to SEC (Form 4). Jounce Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 5 May 2023.
The full history, which starts in 2017, counts 6 purchases against 89 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
167
Thresholds
n/a
Buy Volume
€10M
6 ops. · all time
Sell Volume
€36M
89 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$43.8M
Last declaration on 5 May 2023
Declarations167 total
10,000 shares@ US$9,737.70Common StockSEC:0001209191-23-027688:1
5,300,087 shares@ US$1.8599.3% of flowCommon StockSEC:0001209191-23-027688:0
10,000 shares@ US$0.9738100.0% of flowCommon StockSEC:0001209191-23-027692:0
40,267 sharesCommon StockSEC:0001640455-23-000107:1
33,875 sharesCommon StockSEC:0001640455-23-000110:1
60,975 sharesCommon StockSEC:0001640455-23-000110:0
188,778 sharesCommon StockSEC:0001640455-23-000112:0
5,000 sharesCommon StockSEC:0001640455-23-000111:0
25,751 sharesCommon StockSEC:0001640455-23-000107:0
39,228 shares@ US$1.8538.2% of flowCommon StockSEC:0001640455-23-000053:0
20,286 shares@ US$1.018Common StockSEC:0001209191-23-018721:1
Canonical exit: 12 Jun 2023 (T+90)
65,701 shares@ US$0.9940.7% of flowCommon StockSEC:0001209191-23-018721:0
Canonical exit: 11 Jun 2023 (T+90)
7,781 shares@ US$1.12Common StockSEC:0001640455-23-000009:1
5,126 shares@ US$1.12Common StockSEC:0001640455-23-000011:1
9,182 shares@ US$1.12Common StockSEC:0001640455-23-000008:1
24,879 shares@ US$1.12Common StockSEC:0001640455-23-000010:1
7,452 shares@ US$1.1025.6% of flowCommon StockSEC:0001640455-23-000008:0
20,191 shares@ US$1.1012.0% of flowCommon StockSEC:0001640455-23-000010:0
4,159 shares@ US$1.1018.1% of flowCommon StockSEC:0001640455-23-000011:0
6,315 shares@ US$1.1018.0% of flowCommon StockSEC:0001640455-23-000009:0
20,000 shares0Common StockSEC:0001640455-22-000084:0
27,500 shares0Common StockSEC:0001640455-22-000018:0
42,500 shares0Common StockSEC:0001640455-22-000019:0
27,500 shares0Common StockSEC:0001640455-22-000016:0
87,500 shares0Common StockSEC:0001640455-22-000017:0
25 of 167 declarations
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. is a U.S. biotechnology company historically focused on cancer immunotherapy and predictive biomarker discovery. Headquartered in Cambridge, Massachusetts, United States, the company was listed on the U.S. NASDAQ market under the ticker JNCE. From an equity-analysis perspective, Jounce fit the profile of a development-stage biotech: value creation depended primarily on clinical data, intellectual property, and access to capital rather than on commercial product revenue. Its strategy centered on enabling the immune system to attack tumors and on using biomarker-driven science to identify patients most likely to benefit from therapy.([sec.gov](https://www.sec.gov/Archives/edgar/data/1640455/000164045523000066/jnce-20221231.htm))
Founded within the Cambridge biopharma ecosystem, Jounce built its pipeline around several oncology immunotherapy assets, including vopratelimab, JTX-8064, and pimivalimab, with earlier-stage programs such as JTX-1484 and GS-1811 also referenced in SEC filings. The company stated that it operated only in the United States, and its business model relied heavily on patents, licensed intellectual property, and long development timelines typical of early-stage biotech. Like many clinical-stage peers, Jounce needed external financing, collaborations, licensing agreements, and strategic alliances to support future development efforts.([sec.gov](https://www.sec.gov/Archives/edgar/data/1640455/000164045523000066/jnce-20221231.htm))
Read moreShow less
Competitive positioning was shaped by the intensely crowded immuno-oncology landscape, where larger pharmaceutical groups and better-capitalized biotech companies could often advance programs faster. Jounce’s differentiator was its science platform, which combined checkpoint-targeting antibodies with biomarker research in an effort to improve response selection and clinical success rates. That approach offered optionality, but it also carried the usual biotech risks: clinical uncertainty, regulatory hurdles, and a high cost of capital.([sec.gov](https://www.sec.gov/Archives/edgar/data/1640455/000164045523000066/jnce-20221231.htm))
The key recent corporate event was the company’s March 2023 announcement that it had entered into a definitive merger agreement for Concentra Biosciences to acquire Jounce for $1.85 per share in cash plus a contingent value right. The company also disclosed an approximately 84% workforce reduction as part of the transaction process, underscoring a major strategic reset. For investors, that means Jounce should be viewed less as a going-concern growth biotech and more as a former NASDAQ-listed United States oncology platform whose near-term story was dominated by acquisition and asset-monetization dynamics.([sec.gov](https://www.sec.gov/Archives/edgar/data/1640455/000164045523000040/jnceexhibit991.htm))
